Treating fatty liver disease by modulating mitochondrial pyruvate metabolism

Jerry R. Colca; William G. McDonald; Kyle McCommis; Brian N. Finck

doi:10.1002/hep4.1036

Treating fatty liver disease by modulating mitochondrial pyruvate metabolism

Jerry R. Colca, William G. McDonald, Kyle McCommis, Brian N. Finck

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

Modifying the entry of pyruvate into mitochondria may provide a unique approach to treat metabolic disease. The pharmacology of a new class of insulin sensitizers directed against a newly identified mitochondrial target may treat many aspects of nonalcoholic steatohepatitis, including fibrosis. This commentary suggests treating nonalcoholic steatohepatitis through a newly identified mechanism consistent with pathophysiology. (Hepatology Communications 2017;1:193-197).

Original language	English
Pages (from-to)	193-197
Number of pages	5
Journal	Hepatology Communications
Volume	1
Issue number	3
DOIs	https://doi.org/10.1002/hep4.1036
State	Published - 2017

Access to Document

10.1002/hep4.1036

Cite this

@article{da2d5dfcf3424954acd9b309b5d30c02,

title = "Treating fatty liver disease by modulating mitochondrial pyruvate metabolism",

abstract = "Modifying the entry of pyruvate into mitochondria may provide a unique approach to treat metabolic disease. The pharmacology of a new class of insulin sensitizers directed against a newly identified mitochondrial target may treat many aspects of nonalcoholic steatohepatitis, including fibrosis. This commentary suggests treating nonalcoholic steatohepatitis through a newly identified mechanism consistent with pathophysiology. (Hepatology Communications 2017;1:193-197).",

author = "Colca, {Jerry R.} and McDonald, {William G.} and Kyle McCommis and Finck, {Brian N.}",

note = "Publisher Copyright: {\textcopyright} 2017 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases.",

year = "2017",

doi = "10.1002/hep4.1036",

language = "English",

volume = "1",

pages = "193--197",

journal = "Hepatology Communications",

issn = "2471-254X",

number = "3",

}

TY - JOUR

T1 - Treating fatty liver disease by modulating mitochondrial pyruvate metabolism

AU - Colca, Jerry R.

AU - McDonald, William G.

AU - McCommis, Kyle

AU - Finck, Brian N.

PY - 2017

Y1 - 2017

N2 - Modifying the entry of pyruvate into mitochondria may provide a unique approach to treat metabolic disease. The pharmacology of a new class of insulin sensitizers directed against a newly identified mitochondrial target may treat many aspects of nonalcoholic steatohepatitis, including fibrosis. This commentary suggests treating nonalcoholic steatohepatitis through a newly identified mechanism consistent with pathophysiology. (Hepatology Communications 2017;1:193-197).

AB - Modifying the entry of pyruvate into mitochondria may provide a unique approach to treat metabolic disease. The pharmacology of a new class of insulin sensitizers directed against a newly identified mitochondrial target may treat many aspects of nonalcoholic steatohepatitis, including fibrosis. This commentary suggests treating nonalcoholic steatohepatitis through a newly identified mechanism consistent with pathophysiology. (Hepatology Communications 2017;1:193-197).

UR - http://www.scopus.com/inward/record.url?scp=85046050144&partnerID=8YFLogxK

U2 - 10.1002/hep4.1036

DO - 10.1002/hep4.1036

M3 - Article

C2 - 29404453

AN - SCOPUS:85046050144

SN - 2471-254X

VL - 1

SP - 193

EP - 197

JO - Hepatology Communications

JF - Hepatology Communications

IS - 3

ER -

Treating fatty liver disease by modulating mitochondrial pyruvate metabolism

Abstract

Access to Document

Other files and links

Fingerprint

Cite this